Sand I C, Brody S L, Wrenn K D, Slovis C M
Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303.
Am J Emerg Med. 1991 Mar;9(2):161-3. doi: 10.1016/0735-6757(91)90182-j.
The authors report their experience using esmolol, an ultra-short acting beta-adrenergic antagonist, for the treatment of seven patients with cocaine-associated cardiovascular complications. No consistent hemodynamic benefit was found with the use of this drug. Although there was a decline in mean heart rate of 23% (range 0% to 35%), they were unable to show a consistent antihypertensive response. Adverse effects occurred in three patients. This included one patient with a marked exacerbation of hypertension and one who became hypotensive. Another patient developed emesis and lethargy during esmolol therapy and required endotracheal intubation. They do not recommend the routine use of esmolol for cocaine cardiotoxicity.
作者报告了他们使用艾司洛尔（一种超短效β-肾上腺素能拮抗剂）治疗7例可卡因相关心血管并发症患者的经验。使用该药物未发现一致的血流动力学益处。尽管平均心率下降了23%（范围为0%至35%），但他们未能显示出一致的降压反应。3例患者出现了不良反应。其中包括1例高血压明显加重的患者和1例出现低血压的患者。另1例患者在艾司洛尔治疗期间出现呕吐和嗜睡，需要进行气管插管。他们不建议常规使用艾司洛尔治疗可卡因心脏毒性。
